Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Detalles Bibliográficos
Autores principales: Courrèges, J-P, Vilsbøll, T, Zdravkovic, M, Le-Thi, T, Krarup, T, Schmitz, O, Verhoeven, R, Bugáñová, I, Madsbad, S
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592347/
https://www.ncbi.nlm.nih.gov/pubmed/19183322
http://dx.doi.org/10.1111/j.1464-5491.2008.02484.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592347/
https://www.ncbi.nlm.nih.gov/pubmed/19183322
http://dx.doi.org/10.1111/j.1464-5491.2008.02484.x

Ejemplares similares